

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

BV421 Mouse Anti-Mouse TIGIT Antibody

RRID:AB_2688007

Type: Antibody

Proper Citation

BD Biosciences Cat# 565270, RRID:AB_2688007

Antibody Information

URL: http://antibodyregistry.org/AB_2688007

Proper Citation: BD Biosciences Cat# 565270, RRID:AB_2688007

Target Antigen: TIGIT

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: BV421 Mouse Anti-Mouse TIGIT Antibody

Description: This monoclonal targets TIGIT

Target Organism: mouse

Clone ID: 1G9

Antibody ID: AB_2688007

Vendor: BD Biosciences

Catalog Number: 565270

Record Creation Time: 20231110T034039+0000

Record Last Update: 20260901T052931+0000

Ratings and Alerts

No rating or validation information has been found for BV421 Mouse Anti-Mouse TIGIT Antibody.

No alerts have been found for BV421 Mouse Anti-Mouse TIGIT Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

De la Torre Medina J, et al. (2026) Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway. *Molecular cancer therapeutics*, 25(6), 957.

Friedman DJ, et al. (2026) Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination. *iScience*, 29(2), 114572.

Deliyanti D, et al. (2025) Immunotherapy with low-dose IL-2 attenuates vascular injury in mice with diabetic and neovascular retinopathy by restoring the balance between Foxp3+ Tregs and CD8+ T cells. *Diabetologia*, 68(7), 1559.

Baxter AE, et al. (2023) The SWI/SNF chromatin remodeling complexes BAF and PBAF differentially regulate epigenetic transitions in exhausted CD8+ T cells. *Immunity*, 56(6), 1320.

Jiang Y, et al. (2022) Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. *Cell reports*, 41(4), 111553.

Chow MT, et al. (2019) Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. *Immunity*, 50(6), 1498.

Benci JL, et al. (2016) Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell*, 167(6), 1540.